#United States #New York #Lucid Diagnostics #PAVmed #Canaccord Genuity

Lucid Diagnostics at the Canaccord Genuity MedTech Forum

Lucid Diagnostics Inc. (Nasdaq: LUCD), a pioneering company in the field of cancer prevention medical diagnostics, will make its presence felt at the upcoming Canaccord Genuity MedTech, Diagnostics, and Digital Health Services Forum. Scheduled for November 11, 2026, in New York City, this event is anticipated to provide a platform for discussing groundbreaking advancements in oncology diagnostics.

At the heart of the forum, Dr. Lishan Aklog, the Chairman and CEO of Lucid, is set to lead a panel discussion titled "Promising Oncology Diagnostics Navigating the Reimbursement Roadmap." This session will focus on the challenges and opportunities surrounding reimbursement for innovative diagnostic methods, which are crucial for advancing patient care in oncology. Unfortunately, the panel discussion won't be webcast, but attendees will still benefit from Dr. Aklog's insights into the future of oncology diagnostics.

In addition to the panel, Dr. Aklog and Lucid's Chief Financial Officer, Dennis McGrath, will engage in one-on-one meetings with investors. This direct interaction offers a unique chance for stakeholders to pose questions and gain deeper insights into the company's strategic direction and product offerings. Interested parties are encouraged to arrange these meetings through their Canaccord Genuity representative.

About Lucid Diagnostics

Lucid Diagnostics is a commercial-stage medical diagnostics firm focusing on cancer prevention. As a subsidiary of PAVmed Inc. (Nasdaq: PAVM), the company addresses the pressing issue of gastroesophageal reflux disease (GERD), which is linked to the increased risk of esophageal precancer and cancer. Through its flagship product, the EsoGuard® Esophageal DNA Test, Lucid aims to provide the first commercially available solution for early detection of esophageal cancer, thereby potentially saving lives.

The EsoGuard test, which can be performed using a noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, empowers healthcare providers to screen high-risk patients efficiently. This innovative approach is aligned with Lucid's mission of preventing cancer and reducing cancer mortality rates through early intervention.

The company's commitment to improving patient outcomes is underscored by its dedication to expanding access to these vital diagnostic tools. As part of its ongoing efforts, Lucid Diagnostics continues to work closely with healthcare professionals and stakeholders to promote wider adoption of its products.

Looking Ahead

As Lucid Diagnostics prepares for its participation in the Canaccord Genuity MedTech Forum, the company remains focused on not only advancing its diagnostic technologies but also ensuring that they are within reach for all patients at risk. Engaging in discussions about reimbursement strategies is essential for fostering a healthcare environment that prioritizes early detection and preventive care.

The forward-looking statements made by the company highlight the various challenges it may face, including regulatory approvals and market acceptance. Nevertheless, Lucid Diagnostics is poised to navigate these hurdles actively, pushing toward a future where esophageal cancer can be detected earlier and more effectively.

For further information, interested parties can visit Lucid's website at www.luciddx.com, and more about its parent company can be found at www.pavmed.com. The journey of innovation in cancer prevention continues, spearheaded by passionate leaders in the field.

As the event approaches, anticipation builds around the ideas and insights that will emerge from this gathering of minds focused on transforming the landscape of cancer diagnostics.